Home – CDMO Solutions | Viral Vectors | AAV
Accelerated AAV manufacturing with industry-leading performance
OXB delivers fast, flexible, and high-performance AAV manufacturing solutions to support advanced therapy developers worldwide. Our proprietary inAAVateTM platform can deliver GMP AAV in as little as 7 months and consistently achieves high titres and market leading full-to-empty capsid ratios. Alongside platform projects, clients can also tech transfer-in to OXB or work with us on a custom project.
OXB’s AAV track record
0+
GMP batches successfully released
0
Successful regulatory submissions
0
monthsTo GMP release
0E+
17vgsAt 500L scale
0%
Full capsids
0%
Analytical assays performed in-house
inAAVate™ platform
Accelerating AAV success from design to GMP
OXB’s inAAVate™ platform provides a robust, standardised foundation to help partners achieve clinical and commercial milestones faster. Our end-to-end platform integrates proprietary technologies across construct design, upstream and downstream processing, analytics, and fill/finish.
Clients can access the Triple Plasmid, or Dual Plasmid System, which together with our proprietary transfection process are responsible for increasing bioreactor vg titre up to 10-fold over typical industry standards.
With the inAAVate™ platform, clients can progress from project initiation to their first GMP batch in as little as 7 months.
Explore the inAAVate™ platform
Our platform technologies:
Related resources
Novel Dual-Plasmid Transfection System Improves Titer And Product Quality In AAV Manufacturing
Published in Bioprocess Online, this article explores OXB's novel dual-plasmid system for AAV manufacturing, combining the gene of interest with RepCap in one plasmid and a separate helper plasmid, improving vector genome titers up to 10-fold and increasing full capsid yields to over 90% in the final product.
View PDF >Achieving rAAV Bioreactor Titer of 1E15 vgL With Novel Plasmid Transient Transfection Platform
In this article, published in Cell and Gene, OXB introduces a high cell density transient transfection platform that achieves recombinant AAV (rAAV) vector genome titers exceeding 1E15 vg/L in bioreactor cultures. This platform incorporates optimized medium additives, plasmid design, and process parameters, enabling successful scale-up to 2,000L bioreactors.
View PDF >AAV: Novel Dual-Plasmid Transfection System
This brochureintroduces OXB's novel dual plasmid transfection system for AAV development and manufacture.
View PDF >Why choose OXB as your AAV CDMO?
Accelerating AAV Success from design to GMP
Reach GMP in as little as 7 months
By leveraging the inAAVateTM plug-and-play platform process, the need for excessive process development is eliminated, allowing clients to reach GMP in as little as 7 months.
Maximise commercial viability with more doses per batch
By continually developing innovative technologies, OXB clients can now achieve titres of 1.5E+17vgs from a 500L bioreactor, with 90% full capsids, delivering cost efficiencies through more doses per batch.
Effectively manage budgets and milestones
Our flexible delivery and commercial models ensure clients can effectively manage budgets in line with funding milestones and decision points.
Ways to work with us
There are multiple ways in which pharma, biotechs and start-ups work with us, depending on development phase, scale, and individual IP requirements.
Platform project
For clients that are pre-clinical or early-clinical that wish to reach GMP at an accelerated rate with a proven process.
Custom solution
For clients that are pre-clinical or early-clinical that require flexibility in the manufacture of their drug candidate.
Tech-transfer
For clients in phase I, II, or III that need to transfer their manufacture to a CDMO for scale and/or long-term manufacture.
Frequently asked questions
Platform feasibility in just 6 weeks
For early-stage clients and those that require drug substance for in vitro or in vivo studies, we offer a cost-effective platform feasibility project, including analytics, in just 6 weeks. Test your gene of interest (GOI) in the inAAVateTM platform.
